|04 November 2016||Nexvet Reports Financial Results for First Quarter of Fiscal Year 2017|
|DUBLIN, Ireland, Nov. 04, 2016 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET) today announced its financial results for the three month period ended September 30, 2016.
Recent highlights include:
Advanced preparations for pivotal studies of the anti-NGF mAb therapy frunevetmab for cats and a pivotal safety study of the anti-NGF mAb therapy ranevetmab for dogs
Initiated a pivotal target animal safety study of frunevetmab in October
Announced publication of two peer-reviewed ar... |
|19 October 2016||Nexvet to Present at the 25th Annual Credit Suisse Healthcare Conference|
|DUBLIN, Ireland, Oct. 19, 2016 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET), a veterinary biologic therapy developer, today announced that its Chief Executive Officer, Dr. Mark Heffernan, is scheduled to present at the 25th Annual Credit Suisse Healthcare Conference in Scottsdale, AZ on Monday, November 7th at 11:00AM MT.
Dr. Heffernan will provide an overview of Nexvet’s pivotal-stage clinical programs for chronic pain in cats and dogs, as well as its therapies in development in the ... |
|02 September 2016||Nexvet Biopharma Reports Full Year Fiscal 2016 Results|
|DUBLIN, Ireland, Sept. 02, 2016 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET), a veterinary biologic therapeutics company, today announced financial results for its 2016 fiscal year, which concluded on June 30, 2016.
Announced positive data from a multi-center, placebo-controlled, randomized, double-blind pivotal efficacy and field safety study of ranevetmab (or ‘NV-01’), which enrolled 262 dogs with naturally occurring osteoarthritis and met its primary endp... |
|20 July 2016||Nexvet Announces Publication of Two Peer-Reviewed Journal Articles Profiling Frunevetmab (NV-02) and Presentation at the Veterinary Pain Short Course Conference|
|DUBLIN, Ireland, July 20, 2016 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET), a veterinary biologic therapeutics company, today announced the recent publication of two peer-reviewed papers regarding frunevetmab in the Journal of Veterinary Internal Medicine (JVIM), as well as an upcoming presentation by Nexvet’s Chief Scientific Officer Dr. David Gearing at the Veterinary Pain Short Course in San Diego, California on July 29, 2016. Frunevetmab (“NV-02”) is Nexvet’s anti-nerve growth facto... |